NCT05470647View on ClinicalTrials.gov

A Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

August 17, 2022

Primary Completion Date

September 24, 2022

Study Completion Date

December 28, 2022

Conditions
Allergic Rhinitis
Interventions
BIOLOGICAL

Interleukin-4 receptor responders 1

Interleukin-4 receptor was injected subcutaneously.

BIOLOGICAL

Interleukin-4 receptor responders 2

Interleukin-4 receptor was injected subcutaneously.

BIOLOGICAL

Placebo

Placebo was injected subcutaneously.

Trial Locations (1)

100000

Beijing Tongren Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER